198 related articles for article (PubMed ID: 12832225)
1. Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.
Archer T; Palomo T; McArthur R; Fredriksson A
Neurotox Res; 2003; 5(1-2):95-110. PubMed ID: 12832225
[TBL] [Abstract][Full Text] [Related]
2. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
Breese GR; Napier TC; Mueller RA
J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
[TBL] [Abstract][Full Text] [Related]
4. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats.
Brus R; Kostrzewa RM; Nowak P; Perry KW; Kostrzewa JP
Neurotox Res; 2003; 5(5):329-38. PubMed ID: 14715452
[TBL] [Abstract][Full Text] [Related]
5. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
[TBL] [Abstract][Full Text] [Related]
6. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
7. Behavioural supersensitivity following neonatal 6-hydroxydopamine: attenuation by MK-801.
Archer T; Fredriksson A
Neurotox Res; 2007 Sep; 12(2):113-24. PubMed ID: 17967735
[TBL] [Abstract][Full Text] [Related]
8. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
[TBL] [Abstract][Full Text] [Related]
9. Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice.
Fredriksson A; Plaznik A; Sundström E; Archer T
Pharmacol Toxicol; 1994 Jul; 75(1):36-41. PubMed ID: 7971733
[TBL] [Abstract][Full Text] [Related]
10. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
[TBL] [Abstract][Full Text] [Related]
11. Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats.
Gong L; Kostrzewa RM; Brus R; Fuller RW; Perry KW
Brain Res Dev Brain Res; 1993 Nov; 76(1):59-65. PubMed ID: 8306431
[TBL] [Abstract][Full Text] [Related]
12. Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of brain dopamine depletion.
Miller FE; Heffner TG; Kotake C; Seiden LS
Brain Res; 1981 Dec; 229(1):123-32. PubMed ID: 6796194
[TBL] [Abstract][Full Text] [Related]
13. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
Tariq M; Khan HA; Al Moutaery K; Al Deeb S
Brain Res Bull; 2001 Jan; 54(1):77-82. PubMed ID: 11226716
[TBL] [Abstract][Full Text] [Related]
15. The expression of proenkephalin and prodynorphin genes and the induction of c-fos gene by dopaminergic drugs are not altered in the straitum of MPTP-treated mice.
Ziolkowska B; Horn G; Kupsch A; Höllt V
J Neural Transm Park Dis Dement Sect; 1995; 9(2-3):151-64. PubMed ID: 8527000
[TBL] [Abstract][Full Text] [Related]
16. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
Hu XT; Wachtel SR; Galloway MP; White FJ
J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
[TBL] [Abstract][Full Text] [Related]
17. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
Fredriksson A; Palomo T; Archer T
J Neural Transm (Vienna); 1999; 106(9-10):889-909. PubMed ID: 10599871
[TBL] [Abstract][Full Text] [Related]
18. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine.
Depoortere R; Perrault G; Sanger DJ
Psychopharmacology (Berl); 1996 Apr; 124(3):231-40. PubMed ID: 8740044
[TBL] [Abstract][Full Text] [Related]
19. Neonatal 6-hydroxydopamine and adult SKF 38393 treatments alter dopamine D1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats.
Gong L; Kostrzewa RM; Li C
J Neurochem; 1994 Oct; 63(4):1282-90. PubMed ID: 7931280
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine and quinpirole, but not 7-OH-DPAT or SKF 38393, potentiate the inhibitory effect of L-NAME on ethanol-induced locomotor activity in mice.
Uzbay IT; Kayir H
Naunyn Schmiedebergs Arch Pharmacol; 2003 Apr; 367(4):414-21. PubMed ID: 12690434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
